Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome.

Haematologica · 2019 · PMC6312014 · PMID 30171030

Europe PMC DOI

hedged sentences

0.0700

closest p · 1.4× alpha

0.0800

boldest claim

The sentences

showed a trendP =0.07so close (0.05 < p ≤ 0.1)

The secondary endpoints, progression-free survival and AML-free survival were also investigated and showed a trend to a more favorable outcome for patients with elevated HbF: the median progression-free survival was 7.7 months versus 2.4 months (HR=0.32; 95% CI: 0.10–1.10; P =0.07) ( Figure 3B ) and the median AML-free survival was 13.1 months versus 7.6 months (HR=0.42; 95% CI: 0.13–1.38; P =0.15) ( Figure 3C ).

also in 53,322 other papers

borderline significantP =0.08so close (0.05 < p ≤ 0.1)

A borderline significant association was also observed between HbF levels after two courses of treatment and hemoglobin levels after four courses (r s =0.36, P =0.08) ( Figure 2C ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.